Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Cancer - Gynecologic Cancer
Title   GOG 274: A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Summary   The aim of this study is to test the potential benefit of the addition of chemotherapy following completion of primary chemoradiation for patients with locally advanced cervical cancer. The primary objective will be to determine if the addition of chemotherapy with Carboplatin and Paclitaxel to standard Cisplatin-based chemoradiation improves overall survival.
Description   Patients will be randomized to one of two possible treatment arms. Patients in both arms will be treated with standard external beam radiation treatment to the pelvis and brachytherapy. Cisplatin will be given during the radiation weekly for 5 doses. Within 4 weeks of completion of all radiation treatment, including the brachytherapy component, and following recovery from toxicities, patients in Arm B will be treated with an additional 4 cycles of 3 weekly adjuvant chemotherapy using Carboplatin and Paclitaxel.
IRB Number   13012
Inclusion/Notes   To be eligible for this study, patients must meet several criteria, including but not limited to the following: Must be at least 18 years old and have stage IB1 & positive nodes, IB2, II, IIIB or IVA cervical cancer, Patients may not have had prior chemotherapy or radiation therapy for cervical cancer, May not have prior history of Crohn's Disease or ulcerative colitis or any prior malignancies within 5 years
Status   Open
Start Date   03/21/2013
Principal Name   Eva Chalas, MD
Contact Name   Christina Egan, RN
Fax   516-663-1871
Current Trial Type   Interventional
Phone   516-663-1216
Alternate Phone   516-663-8391